Natera (Natera) Days Payable : 10.96 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Natera Days Payable?

Natera's average Accounts Payable for the three months ended in Dec. 2023 was $18 Mil. Natera's Cost of Goods Sold for the three months ended in Dec. 2023 was $151 Mil. Hence, Natera's Days Payable for the three months ended in Dec. 2023 was 10.96.

The historical rank and industry rank for Natera's Days Payable or its related term are showing as below:

NTRA' s Days Payable Range Over the Past 10 Years
Min: 14.28 Med: 24.72 Max: 46.94
Current: 15.43

During the past 11 years, Natera's highest Days Payable was 46.94. The lowest was 14.28. And the median was 24.72.

NTRA's Days Payable is ranked worse than
90.48% of 210 companies
in the Medical Diagnostics & Research industry
Industry Median: 68.79 vs NTRA: 15.43

Natera's Days Payable declined from Dec. 2022 (23.43) to Dec. 2023 (10.96). It may suggest that Natera accelerated paying its suppliers.

Natera Days Payable Historical Data

The historical data trend for Natera's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natera Days Payable Chart

Natera Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

24.12

14.97

20.23

23.34

14.28

Natera Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															23.43	20.72	18.24	13.14	10.96

Competitive Comparison of Natera's Days Payable

For the Diagnostics & Research subindustry, Natera's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Natera's Days Payable Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Natera's Days Payable distribution charts can be found below:

* The bar in red indicates where Natera's Days Payable falls into.

Natera Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Natera's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (31.148	+	14.998)	/	2 )	/	589.831	*	365
=	23.073					/	589.831	*	365
=	14.28

Natera's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (21.321	+	14.998)	/	2 )	/	151.247	*	365 / 4
=	18.1595					/	151.247	*	365 / 4
=	10.96

Natera Days Payable Related Terms

Thank you for viewing the detailed overview of Natera's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Natera (Natera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Natera Inc (NAS:NTRA) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753

Website

https://www.natera.com

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Executives

Michael Burkes Brophy	officer: Chief Financial Officer	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Steven Leonard Chapman	officer: Chief Operating Officer	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Daniel Rabinowitz	officer: CHIEF LEGAL OFFICER	C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN TX 78753
Jonathan Sheena	director, officer: Chief Technology Officer	C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Gail Boxer Marcus	director	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Rowan E Chapman	director	201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Matthew Rabinowitz	director, officer: Chief Executive Officer	C/O NATERA, INC., 201 INDUSTRIAL ROAD, SUITE 410, SAN CARLOS CA 94070
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Robert Alan Schueren	officer: Chief Operating Officer	7400 PASEO PADRE PARKWAY, FREMONT CA 94555
Roelof Botha	director	C/O SEQUOIA CAPITAL, 2800 SAND HILL RD, SUITE 101, MENLO PARK CA 94025
Herm Rosenman	officer: Chief Financial Officer	OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
Todd C Cozzens	director	ONE FEDERAL STREET, 25TH FLOOR, BOSTON MA 02110
Monica Bertagnolli	director	C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Roy D. Baynes	director	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130